Octreotide therapy for nateglinide-induced hypoglycemia.
Sherk
Daniel K
DK
Bryant
Sean M
SM
D000368:Aged; D001786:Blood Glucose / Q000378:metabolism; D003510:Cyclohexanes / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D005947:Glucose / Q000627:therapeutic use; D006801:Humans; D007003:Hypoglycemia / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D000077715:Nateglinide; D015282:Octreotide / Q000627:therapeutic use*; D010649:Phenylalanine / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome
D001786:Blood Glucose; D003510:Cyclohexanes; D005765:Gastrointestinal Agents; D007004:Hypoglycemic Agents; D000077715:Nateglinide; D010649:Phenylalanine; D005947:Glucose; D015282:Octreotide